Lanman Xu
Impact in
- Hepatology top 5%
- Liver physiology and pathology
- Cancer Research top 10%
- MicroRNA in disease regulation
Papers in
- Epidemiology 16
- Liver Disease Diagnosis and Treatment 14
- Hepatology 11
- Liver Diseases and Immunity 8
- Liver physiology and pathology 2
- Co-authors
- Yongping Chen (21 shared papers)Da‐Zhi Chen (19 shared papers)Feng‐Bin Lu (7 shared papers)En-De Hu (7 shared papers)Jinlu Wu (6 shared papers)Zhuo Lin (13 shared papers)Ming‐Hua Zheng (5 shared papers)Yuewen Gong (6 shared papers)
- Journals
- Toxicology and Applied Pharmacology (2 papers)Frontiers in Physiology (2 papers)Immunology Letters (2 papers)Oxidative Medicine and Cellular Longevity (2 papers)European Journal of Pharmacology (2 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Lanman Xu
36 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 97
- Hepatology 230
- Cancer Research 194
- Genetics 127
- Epidemiology 392
- Pathology and Forensic Medicine 137
Countries citing papers authored by Lanman Xu
This map shows the geographic impact of Lanman Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lanman Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lanman Xu more than expected).
Fields of papers citing papers by Lanman Xu
This network shows the impact of papers produced by Lanman Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lanman Xu. The network helps show where Lanman Xu may publish in the future.
Co-authors
The 25 scholars most cited alongside Lanman Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 197 | |
| 2 | 2018 | 111 | |
| 3 | 2015 | 108 | |
| 4 | 2014 | 92 | |
| 5 | 2017 | 82 | |
| 6 | 2018 | 80 | |
| 7 | 2018 | 78 | |
| 8 | 2016 | 67 | |
| 9 | 2019 | 62 | |
| 10 | 2021 | 49 | |
| 11 | 2022 | 37 | |
| 12 | 2017 | 33 | |
| 13 | Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway. | 2014 | 33 |
| 14 | Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury. | 2015 | 29 |
| 15 | 2019 | 28 | |
| 16 | 2016 | 28 | |
| 17 | 2019 | 22 | |
| 18 | 2014 | 21 | |
| 19 | 2016 | 20 | |
| 20 | 2021 | 17 |
About Lanman Xu
Lanman Xu is a scholar working on Epidemiology, Hepatology, Molecular Biology, Pathology and Forensic Medicine and Immunology, having authored 38 papers that have together received 1.3k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (14 papers), Liver Diseases and Immunity (8 papers), Alcohol Consumption and Health Effects (8 papers), Gut microbiota and health (3 papers), MicroRNA in disease regulation (3 papers), Drug-Induced Hepatotoxicity and Protection (2 papers), Liver physiology and pathology (2 papers) and Metabolism, Diabetes, and Cancer (2 papers). The work is most often cited by research in Hepatology (230 citations), Cancer Research (194 citations), Genetics (127 citations), Epidemiology (392 citations) and Pathology and Forensic Medicine (137 citations). Lanman Xu has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Yongping Chen, Da‐Zhi Chen, Feng‐Bin Lu, En-De Hu, Jinlu Wu, Zhuo Lin, Ming‐Hua Zheng, Yuewen Gong, Yong‐Ping Chen and Xiaoya Jin. Their work appears in journals such as Toxicology and Applied Pharmacology, Frontiers in Physiology, Immunology Letters, Oxidative Medicine and Cellular Longevity and European Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.